Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Current Liabilities (2016 - 2025)

Rein Therapeutics filings provide 10 years of Total Current Liabilities readings, the most recent being $6.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 7.5% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Dec 2025, up 7.5%, and an annual FY2025 reading of $6.2 million, up 7.5% over the prior year.
  • Total Current Liabilities hit $6.2 million in Q4 2025 for Rein Therapeutics, up from $5.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $7.7 million in Q2 2025, with the low at $1.2 million in Q2 2023.
  • Median Total Current Liabilities over the past 5 years was $4.5 million (2022), compared with a mean of $4.5 million.
  • The sharpest move saw Total Current Liabilities crashed 76.76% in 2023, then surged 312.45% in 2024.
  • Year by year, Total Current Liabilities stood at $4.5 million in 2021, then decreased by 24.93% to $3.4 million in 2022, then grew by 29.58% to $4.4 million in 2023, then soared by 31.11% to $5.7 million in 2024, then grew by 7.5% to $6.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $6.2 million, $5.7 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.